• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

脂毒性和炎症诱导的miR-34a升高介导了肝纤维化中肝细胞与肝星状细胞之间的病理生理通讯。

Elevated miR-34a induced by lipotoxicity and inflammation mediates pathophysiological communication between hepatocytes and hepatic stellate cells in liver fibrosis.

作者信息

Duan Qihua, Hu Ruixiang, Chen Yan, Wade Henry, Kaluzny Szczepan, Zhang Bingrui, Wu Rongxue, Liu Guangnan, Wang Cunchuan, Harris Edward N, Su Qiaozhu

机构信息

Institute for Global Food Security, School of Biological Sciences, Queen's University Belfast, Belfast BT9 5DL, United Kingdom.

Department of Gastrointestinal Surgery, First Affiliated Hospital of Jinan University, Guangzhou, Guangdong 510630, China.

出版信息

Genes Dis. 2025 Apr 18;12(6):101648. doi: 10.1016/j.gendis.2025.101648. eCollection 2025 Nov.

DOI:10.1016/j.gendis.2025.101648
PMID:40837409
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12361996/
Abstract

Increased mortality in patients with metabolic dysfunction-associated steatotic liver disease (MASLD) imposes an urgent need to elucidate the pathogenesis of MASLD so that novel therapeutic strategies may be identified. Here, we delineate the mechanism of microRNA-34a-5p (miR-34a) in the progressive liver injury of MASLD and liver fibrosis. Specifically, liver tissue from patients with obesity-associated hepatic steatosis, metabolic dysfunction-associated steatohepatitis (MASH), and fibrosis, as well as liver tissues from a human MASLD-like mouse model, were utilized for this study. We found that lipotoxicity resulting from obesity or saturated free fatty acid treatment induced miR-34a expression in human liver tissue or mouse hepatocytes, which was accompanied by dysregulation of lipoprotein metabolism, activation of inflammation, and ballooning degeneration of hepatocytes. Moreover, increased cellular miR-34a induced by treatment with saturated fat, palmitic acid, or transfection of miR-34a mimic was released from injured hepatocytes into the conditional cell culture media, which mediated pathological communications between hepatocytes and hepatic stellate cells, activated pro-fibrogenic signaling in hepatic stellate cells, and induced extracellular matrix remodeling. These phenotypes were recapitulated in a human MASLD-like mouse model in which MASLD and liver fibrosis were induced via streptozotocin treatment and high-fat feeding. Elevated expression of miR-34a was found in mouse liver tissues, which conveyed the progressive liver injury from steatosis to MASH and liver fibrosis. Our findings demonstrate that elevated miR-34a induced by lipotoxicity and metabolic inflammation are key driving factors in the progressive liver injury from simple steatosis to MASH and liver fibrosis.

摘要

代谢功能障碍相关脂肪性肝病(MASLD)患者死亡率的增加迫切需要阐明MASLD的发病机制,以便确定新的治疗策略。在此,我们阐述了微小RNA-34a-5p(miR-34a)在MASLD进展性肝损伤和肝纤维化中的作用机制。具体而言,本研究使用了肥胖相关肝脂肪变性、代谢功能障碍相关脂肪性肝炎(MASH)和纤维化患者的肝组织,以及人类MASLD样小鼠模型的肝组织。我们发现,肥胖或饱和游离脂肪酸处理导致的脂毒性在人肝组织或小鼠肝细胞中诱导miR-34a表达,这伴随着脂蛋白代谢失调、炎症激活和肝细胞气球样变性。此外,饱和脂肪、棕榈酸处理或转染miR-34a模拟物诱导的细胞内miR-34a增加从受损肝细胞释放到条件细胞培养基中,介导了肝细胞与肝星状细胞之间的病理通讯,并激活了肝星状细胞中的促纤维化信号,诱导细胞外基质重塑。在通过链脲佐菌素处理和高脂喂养诱导MASLD和肝纤维化的人类MASLD样小鼠模型中也出现了这些表型。在小鼠肝组织中发现miR-34a表达升高,这表明从脂肪变性到MASH和肝纤维化的进展性肝损伤。我们的研究结果表明,脂毒性和代谢炎症诱导的miR-34a升高是从单纯脂肪变性到MASH和肝纤维化的进展性肝损伤的关键驱动因素。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3a94/12361996/49c11e952979/gr6.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3a94/12361996/31c59a788d04/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3a94/12361996/04ef1f01f187/gr2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3a94/12361996/de974c3406d8/gr3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3a94/12361996/5111c76b80ac/gr4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3a94/12361996/fd84d9250523/gr5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3a94/12361996/49c11e952979/gr6.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3a94/12361996/31c59a788d04/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3a94/12361996/04ef1f01f187/gr2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3a94/12361996/de974c3406d8/gr3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3a94/12361996/5111c76b80ac/gr4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3a94/12361996/fd84d9250523/gr5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3a94/12361996/49c11e952979/gr6.jpg

相似文献

1
Elevated miR-34a induced by lipotoxicity and inflammation mediates pathophysiological communication between hepatocytes and hepatic stellate cells in liver fibrosis.脂毒性和炎症诱导的miR-34a升高介导了肝纤维化中肝细胞与肝星状细胞之间的病理生理通讯。
Genes Dis. 2025 Apr 18;12(6):101648. doi: 10.1016/j.gendis.2025.101648. eCollection 2025 Nov.
2
Nonalcoholic Fatty Liver非酒精性脂肪肝
3
E2F2 transcription factor promotes a cholestatic MASH phenotype by regulating hepatobiliary metabolism through miR-34a-5p.E2F2转录因子通过miR-34a-5p调节肝胆代谢,促进胆汁淤积性MASH表型。
Hepatology. 2025 Jul 28. doi: 10.1097/HEP.0000000000001461.
4
Multi-modal analysis of human hepatic stellate cells identifies novel therapeutic targets for metabolic dysfunction-associated steatotic liver disease.人肝星状细胞的多模态分析确定了代谢功能障碍相关脂肪性肝病的新治疗靶点。
J Hepatol. 2025 May;82(5):882-897. doi: 10.1016/j.jhep.2024.10.044. Epub 2024 Nov 8.
5
Sodium butyrate ameliorates liver fibrosis in metabolic dysfunction-associated steatohepatitis rats via miR-155-5p/SOCS1/PDGF signaling pathway.丁酸钠通过miR-155-5p/SOCS1/血小板衍生生长因子信号通路改善代谢功能障碍相关脂肪性肝炎大鼠的肝纤维化。
Hepatobiliary Pancreat Dis Int. 2025 Aug;24(4):423-432. doi: 10.1016/j.hbpd.2025.04.006. Epub 2025 Apr 30.
6
The Significance of the Presence of Gilbert's Syndrome in Patients With Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): A Retrospective Cohort Study.吉尔伯特综合征在代谢功能障碍相关脂肪性肝病(MASLD)患者中的意义:一项回顾性队列研究
Cureus. 2025 May 30;17(5):e85074. doi: 10.7759/cureus.85074. eCollection 2025 May.
7
RAP1A suppresses hepatic steatosis by regulating amino acid-mediated mTORC1 activation.RAP1A通过调节氨基酸介导的mTORC1激活来抑制肝脂肪变性。
JHEP Rep. 2024 Dec 18;7(4):101303. doi: 10.1016/j.jhepr.2024.101303. eCollection 2025 Apr.
8
Increased hepatic putrescine levels as a new potential factor related to the progression of metabolic dysfunction-associated steatotic liver disease.肝腐胺水平升高可能是与代谢功能障碍相关的脂肪性肝病进展的新潜在因素。
J Pathol. 2024 Sep;264(1):101-111. doi: 10.1002/path.6330. Epub 2024 Jul 18.
9
Adipose Tissue Macrophages in Metabolic Dysfunction-Associated Steatohepatitis Secrete Extracellular Vesicles That Activate Liver Fibrosis in Obese Male Mice.代谢功能障碍相关脂肪性肝炎中的脂肪组织巨噬细胞分泌细胞外囊泡,激活肥胖雄性小鼠的肝纤维化。
Gastroenterology. 2025 Apr 9. doi: 10.1053/j.gastro.2025.03.033.
10
Liver injury severity determines skeletal deterioration: a shared pathophysiological axis between MASLD and osteoarthritis.肝损伤严重程度决定骨骼退化:非酒精性脂肪性肝病和骨关节炎之间共享的病理生理轴。
Geroscience. 2025 Jul 26. doi: 10.1007/s11357-025-01816-1.

本文引用的文献

1
Mechanistic role of long non-coding RNAs in the pathogenesis of metabolic dysfunction-associated steatotic liver disease and fibrosis.长链非编码RNA在代谢功能障碍相关脂肪性肝病和肝纤维化发病机制中的作用机制
eGastroenterology. 2024 Nov;2(4):e100115. doi: 10.1136/egastro-2024-100115. Epub 2024 Nov 18.
2
New insight of obesity-associated NAFLD: Dysregulated "crosstalk" between multi-organ and the liver?肥胖相关非酒精性脂肪性肝病的新见解:多器官与肝脏之间失调的“串扰”?
Genes Dis. 2022 Jan 28;10(3):799-812. doi: 10.1016/j.gendis.2021.12.013. eCollection 2023 May.
3
MAFLD: How is it different from NAFLD?
MAFLD:与非酒精性脂肪性肝病(NAFLD)有何不同?
Clin Mol Hepatol. 2023 Feb;29(Suppl):S17-S31. doi: 10.3350/cmh.2022.0367. Epub 2022 Nov 29.
4
Global prevalence of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in the overweight and obese population: a systematic review and meta-analysis.超重和肥胖人群中非酒精性脂肪性肝病和非酒精性脂肪性肝炎的全球患病率:一项系统评价和荟萃分析。
Lancet Gastroenterol Hepatol. 2023 Jan;8(1):20-30. doi: 10.1016/S2468-1253(22)00317-X. Epub 2022 Nov 16.
5
Pathophysiological communication between hepatocytes and non-parenchymal cells in liver injury from NAFLD to liver fibrosis.从非酒精性脂肪性肝病到肝纤维化过程中肝损伤中肝细胞与非实质细胞的病理生理学通讯。
Adv Drug Deliv Rev. 2021 Sep;176:113869. doi: 10.1016/j.addr.2021.113869. Epub 2021 Jul 16.
6
Activation of dsRNA-Dependent Protein Kinase R by miR-378 Sustains Metabolic Inflammation in Hepatic Insulin Resistance.dsRNA 依赖性蛋白激酶 R 通过 miR-378 激活维持肝胰岛素抵抗中的代谢炎症。
Diabetes. 2021 Mar;70(3):710-719. doi: 10.2337/db20-0181. Epub 2021 Jan 8.
7
Non-Alcoholic Steatohepatitis: A Review of Its Mechanism, Models and Medical Treatments.非酒精性脂肪性肝炎:其发病机制、模型及医学治疗的综述
Front Pharmacol. 2020 Dec 3;11:603926. doi: 10.3389/fphar.2020.603926. eCollection 2020.
8
CREBH: A Complex Array of Regulatory Mechanisms in Nutritional Signaling, Metabolic Inflammation, and Metabolic Disease.CREBH:营养信号、代谢炎症和代谢性疾病中复杂的调控机制。
Mol Nutr Food Res. 2021 Jan;65(1):e2000771. doi: 10.1002/mnfr.202000771. Epub 2020 Oct 20.
9
The ARRIVE guidelines 2.0: Updated guidelines for reporting animal research.ARRIVE 指南 2.0:报告动物研究的更新指南。
PLoS Biol. 2020 Jul 14;18(7):e3000410. doi: 10.1371/journal.pbio.3000410. eCollection 2020 Jul.
10
Towards a standard diet-induced and biopsy-confirmed mouse model of non-alcoholic steatohepatitis: Impact of dietary fat source.朝着标准化饮食诱导和活检确认的非酒精性脂肪性肝炎小鼠模型迈进:饮食脂肪源的影响。
World J Gastroenterol. 2019 Sep 7;25(33):4904-4920. doi: 10.3748/wjg.v25.i33.4904.